コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 signaling pathway is affected by deletion of diphthamide.
2 PH4, and DPH5 generated viable cells without diphthamide.
3 cidation of the full biosynthesis pathway of diphthamide.
4 compensates for the loss of the +1 charge on diphthamide.
5 through CRISPR/Cas9-mediated knockout of the diphthamide 1 (DPH1) gene, which enable both robust viru
6 on of codon-anticodon interactions involving diphthamide(1) and the hypermodified nucleoside wybutosi
7 hat loss of the intracellular target for DT, diphthamide, a conservative modification of histidine 71
12 ive studies into the potential regulation of diphthamide, and importantly, its ill-defined biological
13 al modification: the conversion of His699 to diphthamide at the tip of domain IV, the region proposed
14 ibosylation of a modified histidine residue, diphthamide, at His715, which blocks protein translation
16 ient with compound heterozygous mutations in Diphthamide Biosynthesis 1 (DPH1) and impaired eEF2 diph
18 vel of DPH4 mRNA and protein, which prevents diphthamide biosynthesis and renders EF2 refractory to H
20 ical evidence showing that the first step of diphthamide biosynthesis in the archaeon Pyrococcus hori
25 The evolutionary conservation of the complex diphthamide biosynthesis pathway throughout eukaryotes i
28 verse number of species, including the yeast diphthamide biosynthesis protein-2, dph2, which suggeste
30 hree decades ago, in vitro reconstitution of diphthamide biosynthesis using purified proteins has not
31 ne in yeast is required for the last step of diphthamide biosynthesis, as the deletion of YBR246W lea
33 ty of yeast to zymocin, is also required for diphthamide biosynthesis, implicating DESR1/KTI11 in mul
34 Interestingly, TORC1 signaling also promotes diphthamide biosynthesis, suggesting that diphthamide fo
39 ncluding the noncanonical radical-SAM enzyme diphthamide biosynthetic enzyme Dph1-Dph2, require at le
40 sing agent that, through ADP ribosylation of diphthamide, causes irreversible inactivation of EF2 and
42 ates the eEF2 functional loss resulting from diphthamide deficiency, possibly because the added +1 ch
45 hthamide is evolutionarily conserved and why diphthamide deletion can cause severe developmental defe
48 es diphthamide biosynthesis, suggesting that diphthamide forms a positive feedback loop to promote tr
49 However, recent progress in dissecting the diphthamide gene network (DPH1-DPH7) from the budding ye
50 ed eukaryotic posttranslational modification diphthamide in eEF2 and tRNA modifications in supporting
58 Our results provide an explanation for why diphthamide is evolutionarily conserved and why diphtham
60 learly emphasizes a pathobiological role for diphthamide, its physiological function is unclear, and
64 ent protein synthesis in eukaryotes requires diphthamide modification of translation elongation facto
65 normal, whereas dph3-/- mice, which lack the diphthamide modification on eEF-2, are embryonic lethal.
68 tion of proteins, establishes a role for the diphthamide modification, and provides evidence of the a
69 mide Biosynthesis 1 (DPH1) and impaired eEF2 diphthamide modification, we observe multiple defects in
71 e inactivation still contained predominantly diphthamide-modified eEF2 and were as sensitive to PE an
72 s that cannot make it strongly suggests that diphthamide-modified EF2 occupies an important and trans
73 S(N)1 type mechanism in which attack of the diphthamide nucleophile lags behind departure of the nic
80 eukaryotic translation elongation factor 2, diphthamide represents one of the most intriguing post-t
81 (R)) of eEF2 by bacterial toxins on a unique diphthamide residue inhibits its translocation activity,
82 toxin catalyzes the ADP ribosylation of the diphthamide residue of eukaryotic elongation factor 2 (e
83 duce cholix, a potent protein toxin that has diphthamide-specific ADP-ribosyltransferase activity aga
84 mpact of complete or partial inactivation on diphthamide synthesis and toxin sensitivity, and to addr
86 ed DT production in the bacteria, as well as diphthamide synthesis and ZAKalpha/p38-driven NLRP1 phos
87 way and the biochemical players required for diphthamide synthesis but also are likely to foster inno
90 ells frequently acquired deficiencies in the diphthamide synthesis pathway, impairing tagraxofusp's a
92 )-containing proteins, resulting in impaired diphthamide synthesis, purine metabolism, nucleotide exc
93 n of the DPH1 gene, encoding a key enzyme in diphthamide synthesis, resulted in diphthamide loss.
94 t amidation step, with Dph6 being the actual diphthamide synthetase catalyzing the ATP-dependent amid
95 We found that yeast protein YLR143W is the diphthamide synthetase catalyzing the last amidation ste
96 we identified the previously unknown enzyme diphthamide synthetase for the last step of diphthamide
98 s region is post-translationally modified to diphthamide, the target for Corynebacterium diphtheriae
102 elongation factor-2 at His(715) that yields diphthamide, the target site for ADP ribosylation by DT
106 and to begin to investigate the function of diphthamide, we generated dph3 knockout mice and showed
107 tant elements of the biosynthetic pathway of diphthamide, which are required for the cytotoxic effect
108 lationally modified histidine residue called diphthamide, which is the target of diphtheria toxin.
109 ationally modified histidine residue, termed diphthamide, which serves as the only target for diphthe
110 in the mutant cells revealed a novel form of diphthamide with an additional methyl group that prevent